LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Elenco Azioni・Cogent Biosciences Inc

Cogent Biosciences Inc

Chiusa

38.64 -1.78

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

37.95

Massimo

38.88

Metriche Chiave
By Trading Economics
Entrata	-22M -102M
EPS	-0.5
Dipendenti	258
EBITDA	-30M -109M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+32.24% upside

Dividendi
By Dow Jones
Utili prossimi	5 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	408M 6B
Apertura precedente	40.42
Chiusura precedente	38.64

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

4.88 / 5.87 Supporto e resistenza

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 feb 2026, 23:53 UTC

Azioni calde

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 feb 2026, 22:23 UTC

Acquisizioni, Fusioni, Takeovers

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

27 feb 2026, 17:55 UTC

Azioni calde

Toronto Stocks Decline, But Remain On Track for Weekly Gains

27 feb 2026, 23:46 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 feb 2026, 23:33 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 feb 2026, 21:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

27 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

27 feb 2026, 21:30 UTC

Utili

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 feb 2026, 21:30 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 feb 2026, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 feb 2026, 21:17 UTC

Utili

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 feb 2026, 21:10 UTC

Acquisizioni, Fusioni, Takeovers

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 feb 2026, 21:09 UTC

Acquisizioni, Fusioni, Takeovers

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 feb 2026, 21:00 UTC

Utili

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 feb 2026, 20:31 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 feb 2026, 20:24 UTC

Discorsi di Mercato

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 feb 2026, 20:23 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27 feb 2026, 20:12 UTC

Discorsi di Mercato

Nike Seen With Further Challenges in China -- Market Talk

27 feb 2026, 19:44 UTC

Discorsi di Mercato

Gold Caps Historic Month -- Market Talk

27 feb 2026, 19:39 UTC

Utili

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 feb 2026, 19:38 UTC

Utili

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

27 feb 2026, 18:53 UTC

Acquisizioni, Fusioni, Takeovers

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

27 feb 2026, 18:45 UTC

Utili

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

27 feb 2026, 18:45 UTC

Discorsi di Mercato

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

27 feb 2026, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

27 feb 2026, 17:07 UTC

Utili

Pemex Cuts 4Q Loss As Operating Results Improve

27 feb 2026, 17:00 UTC

Discorsi di Mercato

Corn Rides Oil Momentum Higher -- Market Talk

27 feb 2026, 16:31 UTC

Discorsi di Mercato

Canadian Economy Shows Resilience -- Market Talk

27 feb 2026, 16:17 UTC

Discorsi di Mercato

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

27 feb 2026, 15:49 UTC

Utili

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

32.24% in crescita

Previsioni per 12 mesi

Media 52.18 USD 32.24%

Alto 67 USD

Basso 35 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.